Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Descending) Administration Route Package Effective Date Package Discontinuation Date Status
51991-0376-17 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 March 31, 2023 No Longer Used
51991-0376-90 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 March 31, 2023 No Longer Used
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
00054-0248-12 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0248-22 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-12 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-13 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-22 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-01 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-02 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-03 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
63459-0177-14 63459-0177 Omacetaxine Mepesuccinate Synribo 3.5 mg/mL Chemotherapy Plant Alkaloid BCR-ABL Subcutaneous Nov. 19, 2012 April 30, 2024 No Longer Used
60505-3628-06 60505-3628 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3629-06 60505-3629 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3630-06 60505-3630 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3631-03 60505-3631 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0233-60 66993-0233 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0234-60 66993-0234 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use

Found 10,000 results in 7 milliseconds — Export these results